Abstract
BackgroundAbatacept, a fusion protein CTLA4Ig1 that selectively modulates coestimulation of T lymphocites, was approved for the treatment of active rheumatoid arthritis (RA) in 2010 as an endovenous (e.v.) biologic therapy....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
